Bagó Biogenesis: A global Leader in Veterinary Vaccines
Table of Contents
Bagó Biogenesis, a company owned by the Sigman and bagó families, operates with a meticulous focus on asepsis, adhering to the most stringent Level 4 biosafety standards. Security measures rival those of a high-security bank vault, a testament to the valuable resources housed within its walls. Inside, rows of steel tanks filled with liquid nitrogen at -150 degrees Celsius hold a strategic reserve of nine Aphyosa virus strains. This reserve serves as a crucial resource for countries like the United States, Canada, and Korea, providing a critical defense against potential outbreaks of this highly contagious disease affecting cattle, sheep, pigs, and goats. Aphyosa fever, as it’s known, causes multi-million dollar losses annually. Bagó Biogenesis’s antigen bank for producing the Aphyosa vaccine is the second largest in the world, second only to a facility in France.
The company’s success is partly attributed to its cutting-edge facilities. It has the most modern plant on the planet and is a world leader in apthosa vaccines,
according to company materials. Its vaccine has received prequalification from the FAO, the United Nations Food and Agriculture association—a seal of excellence shared by only two other, European-based, manufacturers.
In 2024, Bagó Biogenesis invested US$100 million in expanding its operations, utilizing energy from pampa group wind farms to power its 24/7 operations. The research and progress area is a standout feature, but the facility’s most unique element might be its robot nicknamed “bitch,” a name that, while humorous, reflects the machine’s high-speed efficiency in packaging and labeling vaccine doses.
located at kilometer 38.5 of the Pan-American highway,Bagó Biogenesis is part of a larger biotechnology hub,alongside synergium Biotech (focused on complex human medications) and Mabxience (cancer therapies).Together, these companies form Argentina’s leading biotechnology cluster.
Bagó Biogenesis boasts US$250 million in annual revenue, with half coming from international sales. Since 2019,Esteban turic,a veterinarian and scientific researcher with 20 years of experience at the firm,has served as CEO. Turic, 52, has overseen a doubling of the company’s revenue. We have 16 different nationalities among our 1,300 employees,
he stated.
Turic has spearheaded a diversification strategy, aiming to increase the pet-oriented segment from 10% to 20% of the business within five years. This strategy includes the recent acquisition of Animal Mundo in Brazil, a leader in the pet care market. It gives us immediate and direct access to the Brazilian market, the third in importance in company animals, after the US and Europe.We have a production plant in Pinda in the state of San Pablo.And with a very wide portfolio for pets, which we are going to complement it. And we are about to open a Research and Development Center in a plant in Curitiba,
Turic explained. This new center will complement the existing R&D facility in Madrid.
Another key focus is on reproductive health medicines for cattle. The company has invested US$150 million in acquisitions, including a chinese plant in partnership with a Chinese company. We specialize in reproduction in Latin America, in the Middle East and Europe.And we specialize in anti-rabic vaccine as well. Today we are one of the main suppliers worldwide, with almost 40 million doses per year,
Turic described.The company also continues to advance its model plant for aphyosa vaccines in Osong, South Korea, near Seoul, and has completed construction of a vaccine plant in Saudi Arabia.
Awards and Future Plans
Esteban Turic received the 2024 Animal Health Award in the Visionary Leader category, recognizing his contributions to the company’s expansion, including acquisitions in Brazil and China, the establishment of regional offices in asia and the US, and the response to aphyosa outbreaks in Algeria and Libya. The firm is preparing for the next aphyosa vaccination campaign starting in March, aiming to avoid a repeat of the 2001 outbreak that sidelined Argentina from the global market for 14 years. Bagó Biogenesis has adapted to new requirements from Senasa (National Agrifood Health and Quality Service), putting past controversies behind them.
Bagó Biogenesis: Leading the Revolution in Veterinary Vaccines with Innovation and Global impact
Unveiling a World Leader in Veterinary Innovation: A Deep Dive into Bagó Biogenesis’ Global Dominance
At the forefront of veterinary biotechnology, Bagó Biogenesis stands as a global leader in vaccine production, defining standards of excellence, innovation, and strategic partnerships across the globe. We speak with Dr. Laura Vega, a veterinary epidemiologist with over 25 years of experience in vaccine advancement and global health strategies, to uncover the intricacies and future directions of this powerhouse.
Bagó Biogenesis: A Global leader in Aphyosa Vaccines
Editor: Bagó Biogenesis is renowned for its Aphyosa vaccines,which safeguard livestock from this contagious and economically devastating disease. What makes Bagó’s approach so exceptional in comparison to other global manufacturers?
Dr. Laura Vega: Bagó Biogenesis has carved out a unique position in the world of veterinary vaccines through its unparalleled focus on asepsis and biosafety. Emulating security standards akin to a high-security vault, the company ensures the integrity and safety of its highly valued Aphyosa virus strains. Operating under stringent Level 4 biosafety standards, Bagó is equipped to handle and store these virus strains at -150 degrees Celsius, ensuring they’re always ready for global demand. This is further underscored by its antigen bank for Aphyosa vaccines being the second-largest in the world—a statistic driven by its strategic reserves and global partnerships.
A Modern Facility with Timeless Innovations
Editor: The company’s cutting-edge facilities are often highlighted in industry discussions. Could you elaborate on how these state-of-the-art infrastructures contribute to Bagó’s global leadership?
Dr. Laura Vega: Bagó Biogenesis stands out due to its modern production facilities, hailed as the most advanced on the planet. Their commitment to technology is evident in their use of energy-efficient resources, such as harnessed wind power from the Pampa Group. Yet, arguably the most novel innovation is their high-speed packaging robot, humorously nicknamed “bitch,” which echoes the company’s blend of humor and high efficiency. this robot optimizes vaccine production, ensuring that doses are packaged and labeled with remarkable agility and precision.
Strategic Acquisitions and an Eye on the Future
Editor: Esteban Turic, Bagó’s CEO, has strategically steered the company’s revenue growth through diversified acquisitions. How do these acquisitions align with the larger vision for global expansion and specialization?
Dr. Laura Vega: Esteban Turic’s strategic foresight is evident through meticulous acquisitions aimed at broadening Bagó’s market reach and product offerings. The acquisition of Animal Mundo amplifies Bagó’s presence in Brazil’s pet care market, strengthening its supply chain across the Americas. Furthermore, the development of a new R&D center in Curitiba, alongside an existing facility in madrid, aligns with a multi-regional strategy to enhance innovation capabilities. Additionally, through investments such as a new facility in China, Bagó expands its footprint in reproductive health and anti-rabies vaccines, solidifying its position as a critical player in global veterinary health.
Pathway to Veterinary Excellence: Awards and Global Outreach
Editor: In light of its global achievements and innovative strategies, Esteban Turic recently received the Visionary Leader award in the Animal Health category. What significance does this recognition carry for Bagó Biogenesis?
Dr. Laura Vega: This prestigious award captures the essence of Esteban Turic’s visionary leadership. His strategies—ranging from proven responses to aphyosa outbreaks to readiness for future campaigns—highlight a commitment to excellence in global health security. This award not only acknowledges Bagó’s past successes but also its forward-thinking approach to anticipate future challenges,ensuring that the company remains at the forefront of the veterinary vaccine industry while continuing to set the benchmark for others.
Closing Insight: Embracing Innovation for a Healthier Future
editor: As we look to the future, what do you envision as Bagó Biogenesis’ next steps and their potential global impact in the veterinary health sector?
Dr. Laura Vega: Looking ahead, bagó biogenesis is well-positioned to continue leading the charge in veterinary health innovation. Building on the foundation of global collaborations and a broadening product portfolio, Bagó is poised to not only meet but exceed global health demands. With initiatives like the expansion into pet healthcare markets and cutting-edge R&D facilities, Bagó aims to set new standards in vaccine safety and efficacy, thereby safeguarding animal health worldwide. As they champion innovative solutions and forge new international partnerships, Bagó Biogenesis not only aims to protect livestock but also seeks to revolutionize veterinary health for future generations.
We hope this in-depth exploration of Bagó Biogenesis provides you with valuable insights into an institution that is not just setting standards but also redefining the landscape of veterinary health innovation. We invite you to share your thoughts in the comments or engage further on social media. What do you think about Bagó’s innovative paths and global influence? Join the conversation!